Gyre Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Gyre Therapeutics, Inc. (GYRE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $803.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-03
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $803.00K, a 88.19% decline year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$1.53M, a 126.13% decline year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$16.49M, a 791.82% decline year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$38.00K.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$11.25M.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$1.31M, a 103.50% decline from fiscal 2015.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $37.36M, a 38019.39% increase from fiscal 2014.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $98.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $803.00K 10-Q · filed 2018-05-03 | -$723.00K derived: sum of 2 quarters · filed 2018-05-03 | -$17.21M derived: sum of 3 quarters · filed 2018-05-03 | -$17.25M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | -$18.01M derived: sum of 2 quarters · filed 2018-03-19 | -$18.05M derived: sum of 3 quarters · filed 2018-03-19 | -$11.25M 10-K · filed 2018-03-19 | ||||
| 2017-09-30 | -$16.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$16.52M derived: sum of 2 quarters · filed 2017-11-02 | -$9.73M 10-Q · filed 2017-11-02 | -$3.88M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $6.76M 10-Q · filed 2017-08-03 | $12.60M derived: sum of 3 quarters · filed 2018-05-03 | $14.98M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-03-31 | $6.80M 10-Q · filed 2018-05-03 | $6.78M 10-Q · filed 2017-05-11 | $12.64M derived: sum of 2 quarters · filed 2018-05-03 | $15.02M derived: sum of 3 quarters · filed 2018-05-03 | $9.26M derived: sum of 4 quarters · filed 2018-05-03 | |||
| 2016-12-31 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $8.22M derived: sum of 2 quarters · filed 2018-03-19 | $2.46M derived: sum of 3 quarters · filed 2018-03-19 | -$1.31M 10-K · filed 2018-03-19 | ||||
| 2016-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$3.38M derived: sum of 2 quarters · filed 2017-11-02 | -$7.15M 10-Q · filed 2017-11-02 | $3.83M derived: sum of 4 quarters · filed 2017-11-02 | ||||
| 2016-06-30 | -$5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$9.53M 10-Q · filed 2017-08-03 | $1.44M derived: sum of 3 quarters · filed 2017-08-03 | $27.88M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2016-03-31 | -$3.77M 10-Q · filed 2017-05-11 | $7.20M derived: sum of 2 quarters · filed 2017-05-11 | $33.64M derived: sum of 3 quarters · filed 2017-05-11 | $33.36M derived: sum of 4 quarters · filed 2017-05-11 | ||||
| 2015-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $37.41M derived: sum of 2 quarters · filed 2017-03-08 | $37.14M derived: sum of 3 quarters · filed 2017-03-08 | $37.36M 10-K · filed 2017-03-08 | ||||
| 2015-09-30 | $26.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $26.16M derived: sum of 2 quarters · filed 2016-11-03 | $26.38M 10-Q · filed 2016-11-03 | $26.38M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-06-30 | -$278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$57.00K 10-Q · filed 2016-08-04 | $31.65M 10-Q · filed 2015-07-31 | -$57.00K derived: sum of 3 quarters · filed 2016-08-04 | -$57.00K derived: sum of 4 quarters · filed 2016-08-04 | |||
| 2015-03-31 | $221.00K 10-Q · filed 2016-05-05 | $21.04M 10-Q · filed 2015-05-07 | $221.00K derived: sum of 2 quarters · filed 2016-05-05 | $221.00K derived: sum of 3 quarters · filed 2016-05-05 | -$1.62M derived: sum of 4 quarters · filed 2016-05-05 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $0.00 derived: sum of 2 quarters · filed 2016-03-09 | -$1.84M derived: sum of 3 quarters · filed 2016-03-09 | $98.00K 10-K · filed 2016-03-09 | $33.86M 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 8-K/A 6 month · filed 2015-11-05 | -$1.84M derived: sum of 2 quarters · filed 2015-11-05 | $98.00K 10-Q · filed 2015-11-05 | $19.60M 10-Q · filed 2014-11-06 | -$9.42M derived: sum of 4 quarters · filed 2016-03-09 | |||
| 2014-06-30 | -$1.84M derived: 8-K/A 6 month − 10-Q 3 month · filed 2015-10-23 | $98.00K 8-K/A · filed 2015-10-23 | $9.42M 10-Q · filed 2015-07-31 | -$9.42M derived: sum of 3 quarters · filed 2016-03-09 | ||||
| 2014-03-31 | $1.94M 10-Q · filed 2015-05-07 | -$7.58M derived: sum of 2 quarters · filed 2016-03-09 | ||||||
| 2013-12-31 | -$9.51M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | -$41.00K 10-K · filed 2016-03-09 | $13.41M 10-K · filed 2015-03-16 | |||||
| 2013-09-30 | $9.47M 10-Q · filed 2014-11-06 | |||||||
| 2012-12-31 | $39.82M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |